JP2022525435A5 - - Google Patents
Info
- Publication number
- JP2022525435A5 JP2022525435A5 JP2021559648A JP2021559648A JP2022525435A5 JP 2022525435 A5 JP2022525435 A5 JP 2022525435A5 JP 2021559648 A JP2021559648 A JP 2021559648A JP 2021559648 A JP2021559648 A JP 2021559648A JP 2022525435 A5 JP2022525435 A5 JP 2022525435A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962831123P | 2019-04-08 | 2019-04-08 | |
| US62/831,123 | 2019-04-08 | ||
| PCT/US2020/027071 WO2020210232A1 (en) | 2019-04-08 | 2020-04-07 | Cd19 antibodies and methods of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022525435A JP2022525435A (ja) | 2022-05-13 |
| JP2022525435A5 true JP2022525435A5 (cg-RX-API-DMAC10.html) | 2023-04-13 |
| JP7730295B2 JP7730295B2 (ja) | 2025-08-27 |
Family
ID=72751761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559648A Active JP7730295B2 (ja) | 2019-04-08 | 2020-04-07 | Ｃｄ１９抗体およびこれを使用する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12612456B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3953385A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7730295B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220006065A (cg-RX-API-DMAC10.html) |
| CN (1) | CN114341176A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020270888A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3136251A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL287039A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020210232A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| GB202002581D0 (en) | 2020-02-24 | 2020-04-08 | Gammadelta Therapeutics Ltd | Novel antibodies |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| ES2943063T5 (en) | 2020-08-14 | 2026-05-05 | Gammadelta Therapeutics Ltd | Multispecific anti-tcr delta variable 1 antibodies |
| KR20230160253A (ko) | 2021-02-17 | 2023-11-23 | 감마델타 테라퓨틱스 엘티디 | 항-tcr 델타 가변 1 항체 |
| CA3214628A1 (en) * | 2021-04-06 | 2022-10-13 | Memorial Sloan-Kettering Cancer Center | Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| JP2024546804A (ja) * | 2021-12-15 | 2024-12-26 | ワイ－マブス セラピューティクス， インコーポレイテッド | Ｓａｄａ複合体を含む製剤 |
| CN119350497A (zh) * | 2023-07-24 | 2025-01-24 | 星尘生物科技(上海)有限公司 | 人源化抗cd19单链可变区片段及其用途 |
| WO2025077871A1 (zh) * | 2023-10-13 | 2025-04-17 | 苏州瑞博生物技术股份有限公司 | 缀合物、药物缀合物与组合物及制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2753158A1 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| GB201106357D0 (en) * | 2011-04-14 | 2011-06-01 | Pessi Antonello | Composition and uses thereof |
| AU2013302696B9 (en) * | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US20160326249A1 (en) | 2014-01-15 | 2016-11-10 | Zymeworks Inc. | Bi-specific cd3 and cd19 antigen-binding constructs |
| MX386342B (es) * | 2014-07-25 | 2025-03-18 | Memorial Sloan Kettering Cancer Center | Móleculas de unión a her2 y cd3 biespecíficas. |
| US11820832B2 (en) * | 2014-07-25 | 2023-11-21 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| EA201790719A1 (ru) | 2014-09-26 | 2017-07-31 | Макродженикс, Инк. | Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| EP3529268B1 (en) | 2016-10-19 | 2025-02-26 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
| US11046768B2 (en) * | 2017-01-27 | 2021-06-29 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| KR20190140943A (ko) * | 2017-04-24 | 2019-12-20 | 메모리얼 슬로안 케터링 캔서 센터 | 항-cd33 항체 제제 |
| BR102018008260A2 (pt) | 2017-04-24 | 2020-04-28 | Kite Pharma, Inc. | domínios de ligação ao antígeno humanizado e métodos de uso |
| CA3067351A1 (en) * | 2017-06-15 | 2018-12-20 | Nai-Kong Cheung | Anti-l1-cam antibodies and uses thereof |
| CN109535257B (zh) * | 2017-09-22 | 2021-05-28 | 同润生物医药(上海)有限公司 | 新型双特异性cd3/cd19多肽复合物 |
| IL273484B2 (en) | 2017-09-23 | 2025-12-01 | Memorial Sloan Kettering Cancer Center | A33 antibody compositions and methods of using the same in radioimmunotherapy |
-
2020
- 2020-04-07 CA CA3136251A patent/CA3136251A1/en active Pending
- 2020-04-07 US US17/602,176 patent/US12612456B2/en active Active
- 2020-04-07 CN CN202080041527.2A patent/CN114341176A/zh active Pending
- 2020-04-07 JP JP2021559648A patent/JP7730295B2/ja active Active
- 2020-04-07 EP EP20788168.1A patent/EP3953385A4/en active Pending
- 2020-04-07 KR KR1020217036014A patent/KR20220006065A/ko active Pending
- 2020-04-07 AU AU2020270888A patent/AU2020270888A1/en active Pending
- 2020-04-07 WO PCT/US2020/027071 patent/WO2020210232A1/en not_active Ceased
-
2021
- 2021-10-06 IL IL287039A patent/IL287039A/en unknown